P·01 Products / Immune checkpoint
Clone TG2 · Cat. no. DIA-TG2-M · Distinct from clone TG1
Documented advantages over TG1
Relative statements vs TG1, tissue-bound (tonsil), not generalized (section P·06).
Mouse monoclonal antibody for studying human TIGIT in formalin-fixed, paraffin-embedded tissue. The clone-specific datasheet documents immunogen, detection-system-dependent starting dilutions, epitope retrieval, tonsil as positive control and a membranous lymphocyte staining pattern. TG2 shows higher affinity to TIGIT, stronger staining intensity in tonsil IHC and higher dilutability compared with TG1.
Datasheet DIA-TG2-M (V05, 25 Feb 2025; content identical to V03, 22 Feb 2022) documents identity, immunogen, formulation, reconstitution, storage, FFPE-IHC starting conditions, positive control and a reference image of human tonsil.
Heat-induced epitope retrieval in an autoclave (121 °C, 5 min, Tris-EDTA-citrate pH 7.8); 1:50 for biotin/(strept)avidin-based and 1:100–1:200 for polymer-based detection. A documented artefact note covers weak nuclear/nucleolar signal in some epithelia.
TG2 shows higher affinity to TIGIT, stronger staining intensity in tonsil IHC and higher dilutability compared with TG1 (section P·06).
TG2 reference image and historical TIGIT gallery: section P·03 ↓
P·02 Technical data
| Product | Anti-TIGIT (Human) from Mouse |
|---|---|
| Clone | TG2 (monoclonal) — a separate hybridoma clone; not TG1 |
| Catalog number | DIA-TG2-M |
| Distributor catalog number | ODN-DIA-TG2-M (BIOZOL) |
| Target | TIGIT — T-cell immunoreceptor with Ig and ITIM domains (Gene ID 201633, UniProt Q495A1) |
| Immunogen | Recombinant peptide from the extracellular domain of human TIGIT (amino-acid region and epitope not published) |
| Isotype | Mouse IgG1/κ (datasheet; the previous product page stated “IgG1” without light chain) |
| Host species | Mouse |
| Reactivity | Human |
| Conjugation | Unconjugated |
| Format | 100 µl, lyophilized; antibody purified from culture supernatant |
| Reconstitution | Restore to 100 µl with sterile distilled water; gentle shaking for 10 minutes |
| Formulation | PBS, pH 7.4, 2% BSA, 0.05% sodium azide |
| Applications | IHC on standard FFPE sections (datasheet V05) |
| IHC starting range | 1:50 – 1:200 — 1:50 for biotin/(strept)avidin-based detection, 1:100–1:200 for polymer-based detection; optimal dilution to be determined by the user for tissue, fixation, platform and detection system |
| Epitope retrieval | Heat-induced epitope retrieval required; autoclave 121 °C, 5 min, Tris-EDTA-citrate pH 7.8 recommended |
| Positive control | Tonsil |
| Staining pattern | Membranous (lymphocyte subsets) |
| Comparison with TG1 | Higher affinity to TIGIT, stronger staining intensity in tonsil IHC and higher dilutability compared with TG1 (relative statements, not generalized — section P·06) |
| Storage | Lyophilized at 2–8 °C; long-term at −20 °C (stable for at least one year); reconstituted at 2–8 °C short term (several weeks); avoid repeated freeze/thaw cycles |
| Associated antibodies | DIA-TG1-M (anti-TIGIT, clone TG1) · DIA-R12 (anti-PVRIG/CD112R, clone R12) — as listed in the datasheet; each clone carries its own evidence |
| Status | Research Use Only |
The technical specifications above are documented in datasheet DIA-TG2-M V05 (25 Feb 2025), whose product content is identical to V03 (22 Feb 2022); gene and protein entries link to their registries. No specification, protocol or publication of clone TG1 has been transferred to this table. Each laboratory must validate its own conditions.
P·03 IHC gallery
1 figure from datasheet DIA-TG2-M (V05, content identical to V03), explicitly assigned to clone TG2 there – original ONCOdianova image at the resolution embedded in the PDF: normal human tonsil, the documented positive-control tissue.
Immunohistochemistry of human TIGIT in FFPE tonsil using clone TG2 – normal human tonsil with numerous TIGIT-positive lymphocytes (ONCOdianova reference image, datasheet DIA-TG2-M V05).
Routine formalin-fixed, paraffin-embedded tissue. Image at the resolution embedded in the datasheet PDF (721 × 840 px); identical figure in datasheet V03 (22 Feb 2022).
ONCOdianova reference image · clone TG2 labelled in source document41 cases from the gallery of the previous website, which also formed part of the previous TG2 product page. They document TIGIT-positive lymphocytes in normal lymphatic tissue, mucosa and tumors of various organs.
Strong TIGIT expression in a large number of tumor infiltrating lymphocytes in a seminoma with dense lymphocytic infiltrate.
Strong TIGIT expression in tumor infiltrating lymphocytes in a seminoma with sparse lymphocytic infiltrate.
High fraction of TIGIT positive cells in peritumoral lymphocytes in a case of penis carcinoma.
Low grade neuroendocrine carcinoma with scattered infiltrate containing TIGIT positive lymphocytes.
High grade neuroendocrine carcinoma with focal accumulation of TIGIT positive lymphocytes.
Dense peritumoral and intratumoral infiltrate of TIGIT positive lymphocytes in a case of a poorly differentiated squamous cell carcinoma of the esophagus.
High frequency of TIGIT positive lymphocytes in a lymphoepithelial carcinoma.
Dense peritumoral infiltrate of TIGIT positive lymphocytes in a laryngeal squamous cell carcinoma.
Invasive urothelial carcinoma with dense peritumoral and intratumoral infiltrate of TIGIT positive lymphocytes.
TIGIT IHC, overview and detail.
High frequency of TIGIT positive lymphocytes in a Hodgkin lymphoma.
TIGIT positive lymphocytes are present in the peritumoral and intratumoral lymphocytic infiltrate of a squamous cell carcinoma of the lung.
High frequency of TIGIT positive intratumoral lymphocytes in a squamous cell carcinoma of the lung.
TIGIT positive lymphocytes are located peritumoral but not intratumoral in a squamous cell carcinoma.
Sparse TIGIT positive lymphocytes in a squamous cell carcinoma of the lung with strong desmoplastic reaction.
High density of TIGIT positive lymphocytes in a squamous cell carcinoma of the lung.
TIGIT positive lymphocytes in a bronchioloalveolar carcinoma of the lung.
High frequency of TIGIT positive lymphocytes in an adenocarcinoma of the lung.
High frequency of peritumoral TIGIT positive lymphocytes in a large cell adenocarcinoma of the lung.
Abundant TIGIT positive lymphocytes in an adenocarcinoma of the ampulla of Vater.
High number of TIGIT positive lymphocytes in an angiosarcoma.
Frequent TIGIT positive lymphocytes in a liposarcoma.
TIGIT positive lymphocytes are abundant in a Warthin tumor.
Dense infiltration of an ovarian carcinoma by TIGIT positive lymphocytes.
A cervix uteri squamous cell carcinoma with numerous intratumoral TIGIT positive lymphocytes.
Squamous cell carcinoma of the uterine cervix with peritumoral and intratumoral infiltrate of TIGIT positive lymphocytes.
Squamous cell carcinoma of the uterine cervix with abundant intratumoral infiltrate of TIGIT positive lymphocytes.
Squamous cell carcinoma of the uterine cervix with a high number of intratumoral TIGIT positive lymphocytes.
Peritumoral TIGIT positive lymphocytes in a case of endometrium carcinoma.
High density of TIGIT positive lymphocytes in a medullary breast cancer.
A case of medullary breast cancer with abundant TIGIT positive lymphocytes.
High density of peritumoral and intratumoral TIGIT positive lymphocytes in a medullary breast cancer.
TIGIT positive lymphocytes in the subepithelial tissue of the lip (oral epithelium).
Oral mucosa with TIGIT positive lymphocytes in the subepithelial stroma.
Oral mucosa with intraepithelial and subepithelial TIGIT positive lymphocytes.
Abundant TIGIT positive lymphocytes in the spleen.
TIGIT positive lymphocytes are frequent in the thymus.
Thymus with high number of TIGIT positive lymphocytes.
TIGIT positive lymphocytes are abundant in the mucosa of the appendix.
Appendix mucosa with dense accumulation of TIGIT positive lymphocytes.
Appendix mucosa with TIGIT positive lymphocytes.
Magnification as given in the original file name; overview left, detail right.
All images and legends are original ONCOdianova material. The clone-attributed reference image is the only figure in the TG2 datasheet, extracted from the PDF at its embedded resolution; where the datasheet does not state magnification, dilution or detection, this is said in the legend rather than supplemented. The historical gallery was part of the previous TG2 product page and illustrates the tissues studied with ONCOdianova’s anti-TIGIT immunohistochemistry. None of the images is a performance claim for other laboratories, platforms or protocols.
P·04 Documented starting protocol
Only the TG2 datasheet applies. The procedure below is the “Instructions for Use” section of datasheet DIA-TG2-M V05 (25 Feb 2025; identical wording in V03). The previous TG2 page linked the tech note “TIGIT staining manual + automated” and showed a manual and a Leica Bond RX protocol – both are explicitly documented for clone TG1 there and are not TG2 protocols. No TG2-specific automated-stainer protocol is documented. Dilutions are starting values; each laboratory validates tissue, fixation, platform and detection itself.
P·05 Interpretation guide
The datasheet describes membranous staining of various lymphocyte subtypes and shows human TIGIT in FFPE tonsil stained with clone TG2 – normal tonsil with numerous TIGIT-positive lymphocytes – as the positive control.
The datasheet states that weak non-specific nuclear or nucleolar staining may occur in some epithelial tissues, for example colon cancer. Such signal should not be scored as TIGIT positivity; run positive and negative controls in parallel.
The documented evidence for TG2 is datasheet DIA-TG2-M V05 — identity, immunogen, FFPE-IHC starting conditions, tonsil control and the tonsil reference image — together with the documented comparison versus TG1 (higher affinity, stronger tonsil staining intensity, higher dilutability; section P·06). These comparison statements are relative to TG1 within their documented context and are not generalized. For research use only.
P·06 Comparison with TG1
TG2 has higher affinity than TG1. This is a relative, documented comparison between the two ONCOdianova anti-TIGIT clones; it is not an absolute “high-affinity” product class and makes no comparison with antibodies of other manufacturers.
TG2 shows stronger staining intensity than TG1 in IHC on human tonsil, the documented positive-control tissue of both clones. The observation is tissue-bound and is not generalized to all tissues, FFPE specimens or platforms.
TG2 has higher dilutability than TG1, with a documented IHC-P starting range of 1:50–1:200. Higher dilutability can support more efficient reagent use in IHC workflows; no specific cost savings and no causal link between affinity and dilutability are claimed.
The three statements above are a documented comparison between TG2 and TG1. They are relative statements within this documented comparison and are not generalized beyond it.
P·07 Target background
TIGIT (T-cell immunoreceptor with Ig and ITIM domains; also VSTM3, VSIG9, WUCAM) is an inhibitory receptor of the poliovirus receptor/nectin family. Upon binding its ligands CD155 (PVR) and CD112 (nectin-2), it delivers inhibitory signals to T cells and NK cells (UniProt Q495A1). TIGIT and the co-stimulatory receptor CD226 compete for the same ligands; this TIGIT/CD226 axis regulates human T-cell function.[1, 2]
TIGIT is expressed on subsets of T lymphocytes; expression has been reported on NK cells, regulatory T cells, follicular T-helper cells, memory CD4+ T cells and CD8+ T cells, but not on B cells or naive CD4+ T cells (datasheet summary). TIGIT and CD96 are studied as targets for cancer immunotherapy.[3]
These statements describe the target. They are not evidence for the analytical performance of clone TG2 and do not establish which cell populations TG2 detects in a given specimen. Clone TG2 is a research tool for tissue-based TIGIT studies; it carries no diagnostic or therapeutic claim.
Bracketed numbers refer to the target-literature list below. Target biology is kept separate from clone-specific product claims.
P·08 Publications
Titles quoted verbatim; PubMed status and Crossref metadata (including retraction and correction notices) checked on 29 Aug 2026. One datasheet reference (J Clin Invest 2015) was retracted by the journal in 2024 and is not listed; datasheet reference 5 (Grogan J et al., J Immunother Cancer 2016, 4 Suppl 1: P209) is a congress abstract without a PubMed record and is not listed.
P·09 FAQ
TG2 is a mouse monoclonal antibody (IgG1/κ) raised against a recombinant peptide from the extracellular domain of human TIGIT. It is offered as a research reagent for immunohistochemistry on human formalin-fixed, paraffin-embedded (FFPE) tissue.
DIA-TG2-M is the ONCOdianova catalog number of the anti-TIGIT antibody clone TG2: mouse monoclonal (IgG1/κ), reactivity human, IHC on FFPE tissue, 100 µl lyophilized, tonsil as positive control. The distributor catalog number at BIOZOL is ODN-DIA-TG2-M. For research use only.
TG1 and TG2 are two separate mouse monoclonal hybridoma clones against human TIGIT with separate catalog numbers (DIA-TG1-M and DIA-TG2-M). TG2 is documented by its own datasheet, and shows higher affinity, stronger tonsil staining intensity and higher dilutability compared with TG1. Evidence, protocols and images of one clone do not apply to the other.
Yes. TG2 is documented for IHC on human FFPE tissue: datasheet DIA-TG2-M V05 documents detection-system-dependent starting dilutions (overall 1:50 to 1:200), heat-induced epitope retrieval, tonsil as positive control and a membranous lymphocyte staining pattern. For research use only.
The datasheet states 1:50 for biotin/(strept)avidin-based detection and 1:100 to 1:200 for polymer-based peroxidase/DAB detection (overall range 1:50 to 1:200 for IHC on FFPE tissue). The optimal dilution must be determined by the user for each tissue, fixation, platform and detection system.
Heat-induced epitope retrieval is required. The datasheet recommends stringent heat pretreatment in an autoclave at 121 °C for 5 minutes in Tris-EDTA-citrate buffer, pH 7.8 (TEC buffer).
Human tonsil. The datasheet shows normal human tonsil with numerous TIGIT-positive lymphocytes and describes membranous staining of various lymphocyte subtypes.
A membranous staining pattern of various lymphocyte subtypes, shown in the datasheet on human tonsil. The datasheet additionally notes that weak non-specific nuclear or nucleolar staining may occur in some epithelial tissues; such signal should not be scored as TIGIT positivity.
The datasheet states that weak non-specific nuclear or nucleolar staining may occur in some epithelial tissues, for example colon cancer. Such signal should not be scored as TIGIT positivity; positive and negative controls should be run in parallel.
TG2 has higher affinity than TG1. This is a relative statement within the documented comparison context: it does not make TG2 a “high-affinity antibody” in absolute terms, and no comparison with antibodies of other manufacturers is made.
TG2 showed stronger staining intensity in human tonsil IHC compared with TG1. This observation is tissue-bound (tonsil) and is not generalized to all tissues, specimens or platforms; a difference in staining intensity is not by itself a statement on sensitivity or specificity.
TG2 has higher dilutability than TG1. Higher dilutability can support more efficient reagent use in IHC workflows; no specific cost savings are claimed. The documented IHC-P starting range for TG2 is 1:50 to 1:200.
Both ONCOdianova anti-TIGIT clones are documented for IHC on human FFPE tissue with tonsil as positive control. TG2 is documented by its own datasheet, and shows higher affinity, stronger tonsil staining intensity and higher dilutability compared with TG1. Which clone suits a study depends on the application; each laboratory validates its own conditions.
No. “TG2” is the clone name of this anti-TIGIT antibody. It has nothing to do with transglutaminase 2 (TGM2) or anti-transglutaminase autoantibodies.
No. TG2 is intended for research use only and is not intended for diagnostic or therapeutic procedures.
P·10 Documents
Product data, instructions for use, storage, general references and the tonsil reference image.
Download PDF ↓Material safety data sheet (ONCOdianova, all lyophilized antibodies).
Download PDF ↓Ordering. ONCOdianova products are purchased through our distribution partner BIOZOL Diagnostica Vertrieb GmbH, Oehleckerring 11–13, 22419 Hamburg, Germany — order requests by e-mail: order@biozol.de (CC info@oncodianova.com). See also order information and distributors (in preparation).
Datasheet V05 (25 Feb 2025) is the current datasheet for DIA-TG2-M; its product content is identical to V03 (22 Feb 2022); V05 changed only the distributor address. Related: TG1 (separate anti-TIGIT clone) · R12 (CD112R/PVRIG) · KK3 (CD73/NT5E) · TC8 (CD8) · FX3 (FOXP3).